Insider · CIK 0001733077
Robert W. Ross
Files at XLO (Xilio Therapeutics, Inc.), OBX (Obsidian Therapeutics, Inc.). First filing -, latest -.
In brief
Robert W. Ross files SEC Form 4 as director at XLO (Xilio Therapeutics, Inc.), and also at OBX (Obsidian Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Robert W. Ross has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | OBX Obsidian Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,653 | $0.00 | $0 | 37,653 | Aug 5, 2026 |
| Jun 11, 2026 | XLO Xilio Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 12, 2026 |
| Jun 11, 2025 | XLO Xilio Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jun 12, 2025 |
Questions about Robert W. Ross
Answered from the filings on this page, as of the latest one.
Is Robert W. Ross buying or selling?
Robert W. Ross has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Robert W. Ross's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert W. Ross has 0.
Where does Robert W. Ross file Form 4?
Robert W. Ross has filed Form 4 at XLO (Xilio Therapeutics, Inc.); OBX (Obsidian Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.